Develops and manufactures a wide range of therapeutic dosage forms. Specializes in small molecule therapeutic development. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (-1% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.9× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 59% below its peak. The market has trimmed its expectations for the company.
The company sells $94.6M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 26 buys and 12 sells. Management buying with its own money is usually read as a good sign.
A loss of $13.3M against $94.6M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.